Do analysts prefer DRCT or TRAW?

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Direct Digital. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Direct Digital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is DRCT or TRAW more profitable?

Traws Pharma has a net margin of 0.00% compared to Direct Digital's net margin of -74.38%. Direct Digital's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Direct Digital -74.38% N/A -68.48% Traws Pharma N/A -23,868.92% -165.52%

Does the media favor DRCT or TRAW?

In the previous week, Direct Digital had 1 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for Direct Digital and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 0.00 beat Direct Digital's score of -0.13 indicating that Traws Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Direct Digital 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SLGL or TRAW?

In the previous week, Sol-Gel Technologies had 7 more articles in the media than Traws Pharma. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 2 mentions for Traws Pharma. Sol-Gel Technologies' average media sentiment score of 0.76 beat Traws Pharma's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sol-Gel Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SCLX or TRAW?

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is SCLX or TRAW more profitable?

Traws Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Scilex -1,414.57% N/A -147.00% Traws Pharma N/A -23,868.92% -165.52%

Is MIRA or TRAW more profitable?

MIRA Pharmaceuticals' return on equity of -106.95% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -106.95% -104.18% Traws Pharma N/A -23,868.92% -165.52%

Does the media favor MIRA or TRAW?

In the previous week, MIRA Pharmaceuticals and MIRA Pharmaceuticals both had 2 articles in the media. MIRA Pharmaceuticals' average media sentiment score of 0.55 beat Traws Pharma's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ADXS or TRAW?

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Traws Pharma 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is ADXS or TRAW more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Traws Pharma N/A -23,868.92% -165.52%

Traws Pharma (TRAW) Competitors

$0.45 -0.04 (-7.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.44 0.00 (-0.49%)

As of 10/9/2026 07:39 PM Eastern

Compare

TRAW vs. DRCT, SLGL, SCLX, MIRA, and ADXS

Should you buy Traws Pharma stock or one of its competitors? Traws Pharma's main competitors and comparable companies include Direct Digital (DRCT), Sol-Gel Technologies (SLGL), Scilex (SCLX), MIRA Pharmaceuticals (MIRA), and Ayala Pharmaceuticals (ADXS). Companies are selected based on similarities in market, industry, and size.

How does Traws Pharma compare to Direct Digital?

Direct Digital (NASDAQ:DRCT) and Traws Pharma (NASDAQ:TRAW) are related small-cap companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Traws Pharma has a consensus price target of $1.00, indicating a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Traws Pharma is more favorable than Direct Digital.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Direct Digital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Traws Pharma has lower revenue, but higher earnings than Direct Digital. Traws Pharma is trading at a lower price-to-earnings ratio than Direct Digital, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Direct Digital	$30.91M	0.01	-$18.95M	-$156.85	N/A
Traws Pharma	$2.79M	2.45	$9.17M	-$1.74	N/A

In the previous week, Direct Digital had 1 more articles in the media than Traws Pharma. MarketBeat recorded 3 mentions for Direct Digital and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 0.00 beat Direct Digital's score of -0.13 indicating that Traws Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Direct Digital	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Traws Pharma has a net margin of 0.00% compared to Direct Digital's net margin of -74.38%. Direct Digital's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Direct Digital	-74.38%	N/A	-68.48%
Traws Pharma	N/A	-23,868.92%	-165.52%

Direct Digital has a beta of 5.33, meaning that its share price is 433% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

4.0% of Direct Digital shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 25.6% of Direct Digital shares are held by company insiders. Comparatively, 7.6% of Traws Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Traws Pharma beats Direct Digital on 8 of the 15 factors compared between the two stocks.

How does Traws Pharma compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Sol-Gel Technologies has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Sol-Gel Technologies presently has a consensus target price of $197.50, indicating a potential upside of 175.18%. Traws Pharma has a consensus target price of $1.00, indicating a potential upside of 124.62%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Sol-Gel Technologies is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

26.2% of Sol-Gel Technologies shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 66.5% of Sol-Gel Technologies shares are owned by company insiders. Comparatively, 7.6% of Traws Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Traws Pharma has lower revenue, but higher earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	12.10	-$6.13M	-$5.64	N/A
Traws Pharma	$2.79M	2.45	$9.17M	-$1.74	N/A

In the previous week, Sol-Gel Technologies had 7 more articles in the media than Traws Pharma. MarketBeat recorded 9 mentions for Sol-Gel Technologies and 2 mentions for Traws Pharma. Sol-Gel Technologies' average media sentiment score of 0.76 beat Traws Pharma's score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sol-Gel Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Traws Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -910.14%. Sol-Gel Technologies' return on equity of -44.05% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Traws Pharma	N/A	-23,868.92%	-165.52%

Summary

Sol-Gel Technologies beats Traws Pharma on 12 of the 17 factors compared between the two stocks.

How does Traws Pharma compare to Scilex?

Scilex (NASDAQ:SCLX) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Traws Pharma has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
Traws Pharma	N/A	-23,868.92%	-165.52%

Scilex has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Traws Pharma is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Traws Pharma has lower revenue, but higher earnings than Scilex. Traws Pharma is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$31.61M	0.78	-$358.73M	-$49.70	N/A
Traws Pharma	$2.79M	2.45	$9.17M	-$1.74	N/A

69.7% of Scilex shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 4.5% of Scilex shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Traws Pharma had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for Traws Pharma and 1 mentions for Scilex. Scilex's average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
Scilex	Neutral
Traws Pharma	Neutral

Summary

Traws Pharma beats Scilex on 8 of the 14 factors compared between the two stocks.

How does Traws Pharma compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

MIRA Pharmaceuticals has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

In the previous week, MIRA Pharmaceuticals and MIRA Pharmaceuticals both had 2 articles in the media. MIRA Pharmaceuticals' average media sentiment score of 0.55 beat Traws Pharma's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MIRA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Traws Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MIRA Pharmaceuticals currently has a consensus price target of $3.50, suggesting a potential upside of 369.48%. Traws Pharma has a consensus price target of $1.00, suggesting a potential upside of 124.62%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe MIRA Pharmaceuticals is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Traws Pharma has higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.24	N/A
Traws Pharma	$2.79M	2.45	$9.17M	-$1.74	N/A

MIRA Pharmaceuticals' return on equity of -106.95% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-106.95%	-104.18%
Traws Pharma	N/A	-23,868.92%	-165.52%

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 19.9% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

MIRA Pharmaceuticals beats Traws Pharma on 9 of the 13 factors compared between the two stocks.

How does Traws Pharma compare to Ayala Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Traws Pharma had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Traws Pharma	Neutral

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Traws Pharma has lower revenue, but higher earnings than Ayala Pharmaceuticals. Traws Pharma is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Traws Pharma	$2.79M	2.45	$9.17M	-$1.74	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Traws Pharma	N/A	-23,868.92%	-165.52%

Traws Pharma has a consensus target price of $1.00, suggesting a potential upside of 124.62%. Given Traws Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Traws Pharma is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Traws Pharma beats Ayala Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Traws Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRAW vs. The Competition

Export

Metric	Traws Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.38M	$12.31B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.26	797.58	275.02	26.16
Price / Sales	2.45	939.75	635.97	107.44
Price / Cash	0.63	85.97	76.38	53.09
Price / Book	-6.36	10.71	11.22	6.33
Net Income	$9.17M	$2.84B	$3.50B	$382.15M
7 Day Performance	-21.69%	-0.94%	-0.89%	-1.40%
1 Month Performance	-16.24%	-4.89%	-4.42%	-3.47%
1 Year Performance	-85.21%	-4.12%	7.03%	1.18%

Traws Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRAW Traws Pharma	1.5753 of 5 stars	$0.45 -7.3%	$1.00 +124.6%	-85.8%	$7.38M	$2.79M	N/A	7
DRCT Direct Digital	1.0807 of 5 stars	$1.52 -0.7%	N/A	-99.5%	$1.23M	$34.69M	N/A	73	Short Interest Decrease
SLGL Sol-Gel Technologies	3.5697 of 5 stars	$74.28 +2.8%	$197.50 +165.9%	+81.0%	$203.01M	$19.39M	N/A	28	News Coverage Analyst Forecast Analyst Revision
SCLX Scilex	0.2437 of 5 stars	$4.45 +0.9%	N/A	-83.5%	$37.45M	$30.25M	N/A	34	Positive News
MIRA MIRA Pharmaceuticals	2.9856 of 5 stars	$0.84 -3.1%	$3.50 +314.3%	-44.4%	$36.62M	N/A	N/A	2	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRAW) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, SCLX, MIRA, and ADXS

How does Traws Pharma compare to Direct Digital?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Summary

How does Traws Pharma compare to Scilex?

Summary

How does Traws Pharma compare to MIRA Pharmaceuticals?

Summary

How does Traws Pharma compare to Ayala Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Traws Pharma (TRAW) Competitors

TRAW vs. DRCT, SLGL, SCLX, MIRA, and ADXS

How does Traws Pharma compare to Direct Digital?

Do analysts prefer DRCT or TRAW?

Which has better earnings & valuation, DRCT or TRAW?

Does the media favor DRCT or TRAW?

Is DRCT or TRAW more profitable?

Which has more volatility and risk, DRCT or TRAW?

Do institutionals and insiders hold more shares of DRCT or TRAW?

Summary

How does Traws Pharma compare to Sol-Gel Technologies?

Which has more risk and volatility, SLGL or TRAW?

Do analysts recommend SLGL or TRAW?

Do insiders and institutionals believe in SLGL or TRAW?

Which has better earnings & valuation, SLGL or TRAW?

Does the media prefer SLGL or TRAW?

Is SLGL or TRAW more profitable?

Summary

How does Traws Pharma compare to Scilex?

Is SCLX or TRAW more profitable?

Which has more risk & volatility, SCLX or TRAW?

Do analysts rate SCLX or TRAW?

Which has preferable valuation and earnings, SCLX or TRAW?

Do insiders and institutionals hold more shares of SCLX or TRAW?

Does the media prefer SCLX or TRAW?

Summary

How does Traws Pharma compare to MIRA Pharmaceuticals?

Which has more risk and volatility, MIRA or TRAW?

Does the media favor MIRA or TRAW?

Do analysts rate MIRA or TRAW?

Which has better valuation & earnings, MIRA or TRAW?

Is MIRA or TRAW more profitable?

Do insiders and institutionals hold more shares of MIRA or TRAW?

Summary

How does Traws Pharma compare to Ayala Pharmaceuticals?

Do insiders & institutionals have more ownership in ADXS or TRAW?

Does the media refer more to ADXS or TRAW?

Which has more risk and volatility, ADXS or TRAW?

Which has preferable earnings and valuation, ADXS or TRAW?

Is ADXS or TRAW more profitable?

Do analysts rate ADXS or TRAW?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW vs. The Competition

Traws Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools